机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.神经科系统神经内科首都医科大学宣武医院[2]Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, China.[3]State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Hainan, China.[4]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.[5]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China.[6]National Clinical Research Center for Geriatric Diseases, Beijing, China.[7]The Central Hospital of Karamay, Xinjiang, China.
Plasma biomarkers demonstrated potential in identifying amyloid pathology in early Alzheimer's disease. Different subtypes of subjective cognitive decline (SCD) may lead to different cognitive impairment conversion risks.To investigate the differences of plasma biomarkers in SCD subtypes individuals, which were unclear.The 347 individuals were involved, including 93 normal controls (NC), 76 single memory domain SCD (sd-SCD), 79 multidomain SCD (md-SCD), 55 mild cognitive impairment and 44 dementia. We investigated plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL, and GFAP) and neuropsychological scales in the baseline and follow-up. The Kaplan-Meier survival analysis and Cox proportional hazards model were performed to investigate the risk of cognitive decline conversion. The t-test, Mann-Whitney U and multiple linear regression analysis were employed to evaluate the rate of change and correlation between PET-SUVR and plasma biomarker change.In cognitively normal subjects, md-SCD exhibited lower Aβ42/40 and higher p-tau181 and p-tau217 levels. Kaplan-Meier survival analysis revealed that md-SCD group exhibited a higher risk of cognitive decline conversion compared to NC and sd-SCD. Within SCD subgroups, those with positive GFAP status showed higher conversion risk than negative. In the Cox model, the risk of conversion in the md-SCD group was 2.77 times higher than sd-SCD. The md-SCD group demonstrated a faster rate of Aβ42/40 decline than sd-SCD.The study utilized plasma biomarkers to highlight the significance of staging in SCD. In cognitively normal subjects, md-SCD presents a higher risk of cognitive decline than sd-SCD, providing a valuable reference and convenient tool for early identification of individuals at risk for AD.
基金：
National Natural Science
Foundation of China (Grant: 82020108013, 82327809),
STI2030-Major Projects (Grant: 2022ZD0211800), Sino-German
Cooperation Grant (Grant: M-0759), Shenzhen Bay Scholars
Program and Tianchi Scholars Program.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|3 区医学
小类|3 区神经科学
第一作者：
第一作者机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.[3]State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Hainan, China.[4]Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.[5]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China.[6]National Clinical Research Center for Geriatric Diseases, Beijing, China.[7]The Central Hospital of Karamay, Xinjiang, China.
推荐引用方式(GB/T 7714)：
Wei Min,Yu Xianfeng,Hu Shimin,et al.Differences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE[J].Journal Of Alzheimer's Disease : JAD.2025,13872877241309105.doi:10.1177/13872877241309105.
APA：
Wei Min,Yu Xianfeng,Hu Shimin,Hu Wenjing,Shi Rong...&Han Ying.(2025).Differences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE.Journal Of Alzheimer's Disease : JAD,,
MLA：
Wei Min,et al."Differences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE".Journal Of Alzheimer's Disease : JAD .(2025):13872877241309105
